Pharmaceuticals company Pfizer announced Q1FY27 results Financial Highlights: Revenue from Operations: For Q1FY27, the revenue from operations stood at Rs 653.17 crore, marking a YoY growth of 8.31% compared to Rs 603.05 crore in Q1FY26 and a QoQ growth of 3.80% compared to Rs 629.23 crore in Q4FY26. Total Income: The total income for Q1FY27 was Rs 698.01 crore, reflecting an increase of 4.15% YoY from Rs 670.22 crore in Q1FY26 and a 4.19% QoQ increase from Rs 669.95 crore in Q4FY26. Other Income: Other income for the quarter Q1FY27 was Rs 44.84 crore, compared to Rs 67.17 crore in Q1FY26 and Rs 40.72 crore in Q4FY26. Profit Before Tax (and Exceptional Items): The profit before tax and exceptional items for Q1FY27 was Rs 276.68 crore, representing a 6.61% YoY increase from Rs 259.53 crore in Q1FY26 and a 6.51% QoQ increase from Rs 259.78 crore in Q4FY26. Net Profit: The net profit for the period in Q1FY27 reached Rs 204.47 crore, demonstrating a YoY growth of 6.63% from Rs 191.75 crore in Q1FY26 and a QoQ growth of 2.33% from Rs 199.82 crore in Q4FY26. Total Comprehensive Income: For Q1FY27, the total comprehensive income was Rs 203.93 crore, compared to Rs 190.83 crore in Q1FY26 and Rs 203.62 crore in Q4FY26. Earnings Per Share (EPS): The Basic and Diluted EPS for Q1FY27 was Rs 44.69, compared to Rs 41.91 in Q1FY26 and Rs 43.68 in Q4FY26. Annual Performance (FY26): For the full previous year FY26, the company reported a total income of Rs 2,707.60 crore and a net profit of Rs 722.43 crore. Business Highlights: Segment Performance: The Company has only one reporting segment which is 'Pharmaceuticals'. Therefore, separate segment-wise disclosure is not applicable. Subsidiaries: The Company does not have any subsidiary company, associate company, or joint venture company as of June 30, 2026. Exceptional Items (FY26): For the previous year FY26, the company had recorded exceptional items totaling a charge of Rs 49.16 crore. This included Rs 41.73 crore for personnel separation costs related to field force and marketing teams following an exclusive Supply and Marketing Agreement with Cipla Limited for the distribution of brands Corex Dx, Corex LS, Dolonex, and Neksium. Labour Codes Provision: An increase in provision for employee benefits by Rs 7.43 crore was recorded in FY26 following an assessment of the 'New Labour Codes' consolidated by the Government of India. Audit Observation: Figures for the quarter ended March 31, 2026 (Q4FY26), represent the balancing figures between audited figures for the full financial year FY26 and the published year-to-date figures up to the third quarter of that financial year. Result PDF